EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania

Maximilian Buzoianu, Bogdan Adrian Buhas, Mohamad Abou Chakra, Emanuela Ionutas, Mihnea Bogdan Borz, Nicolae Crisan, Michael A O'Donnell

Archivio Italiano di Urologia e Andrologia · 2025

DOI: 10.4081/aiua.2025.14596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archivio Italiano di Urologia e Andrologia, 2025. Verfasst von Maximilian Buzoianu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medicover Hospital, Cluj-Napoca; Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, BCG Vaccine, Practice Patterns, Physicians', Urinary Bladder Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) remains a persistent challenge. This study examines Romanian urologists’ clinical practices, focusing on treatment preferences and awareness of emerging therapies for BCG-unresponsive disease.

Methods

A cross-sectional, web-based survey comprising 24 items was distributed to selected urologists who manage NMIBC via professional mailing lists. Data were collected between May 15 and June 30, 2025.

Results

Out of 400 invited urologists, 216 completed the survey. Radical cystectomy (RC) was the most preferred treatment for BCG-unresponsive NMIBC, recommended by 67% of respondents, followed by tumor resection with surveillance (15%), repeat BCG instillation (14%), and intravesical chemotherapy (4%). Neither clinical trials nor intravenous checkpoint inhibitors were used. Among those using intravesical chemotherapy, gemcitabine was the most commonly used agent (85%), followed by mitomycin C (5%), gemcitabine/docetaxel (4%), gemcitabine/ mitomycin C (3%), docetaxel (2%), and valrubicin (1%). Oncological safety concerns were the main barrier to adopting bladder-sparing therapies. Awareness of FDA-approved therapies for BCG-unresponsive disease, Nadofaragene firadenovec, Nogapendekin alfa inbakicept-pmln, and Pembrolizumab, was limited; 61% of urologists were unaware of all three, and only 1% had used any. BCG shortages were reported by 93% of respondents at some point, who adapted by reducing doses and prioritizing high-grade T1 and CIS cases. Most recognized intravesical chemotherapy as an alternative and were willing to use it if needed.

Conclusions

Though RC remains the predominant approach for BCG-unresponsive cases, over half of urologists’ report using intravesical chemotherapy, reflecting interest in bladder-sparing strategies rather than newly approved FDA agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-Muscle Invasive Bladder NeoplasmsBCG VaccinePractice Patterns, Physicians'Urinary Bladder NeoplasmsHumansRomaniaCross-Sectional StudiesAdministration, IntravesicalCystectomyAntineoplastic AgentsDeoxycytidineMaleGemcitabineFemaleMitomycinSurveys and Questionnaires

Stichwörter der Autor:innen

BCG unresponsiveNon-muscle invasive bladder cancerRomaniapractice patternsurveyurologists

Substanzen

BCG VaccineAntineoplastic AgentsDeoxycytidineGemcitabineMitomycin

Autor:innen und Institutionen

  • Medicover Hospital, Cluj-Napoca; Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca.
  • Medicover Hospital, Cluj-Napoca.
  • Department of Urology, University of Iowa Health Care, Iowa City, IA.
  • Department of Anatomy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures.

Zitieren

APA

Buzoianu, M., Buhas, B. A., Abou Chakra, M., Ionutas, E., Borz, M. B., Crisan, N., & O'Donnell, M. A. (2025). A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania. Archivio Italiano di Urologia e Andrologia. https://doi.org/10.4081/aiua.2025.14596

Vancouver

Buzoianu M, Buhas BA, Abou Chakra M, Ionutas E, Borz MB, Crisan N, et al. A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania. Archivio Italiano di Urologia e Andrologia. 2025. doi:10.4081/aiua.2025.14596

BibTeX
@article{Buzoianu2025,
  author = {Buzoianu, Maximilian and Buhas, Bogdan Adrian and Abou Chakra, Mohamad and Ionutas, Emanuela and Borz, Mihnea Bogdan and Crisan, Nicolae and O'Donnell, Michael A},
  title = {A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania},
  journal = {Archivio Italiano di Urologia e Andrologia},
  year = {2025},
  doi = {10.4081/aiua.2025.14596}
}
Kostenlos starten →